

## Investor briefing – 1H FY2025 Half Year Results

---

**27 February 2025**

**Melbourne, Australia, 27 February 2025:** 4DMedical Limited (ASX: 4DX, “4DMedical”, or the “Company”), a leader in respiratory imaging technology, is pleased to invite shareholders, investors and interested parties to its investor webinar and Q&A session hosted by the Managing Director and Chief Executive Officer, Dr Andreas Fouras.

4DMedical will hold an investor webinar and Q&A session on **Monday, 3 March 2025 at 11.00am AEDT (10.00am AEST)**, where Dr Andreas Fouras will provide an update on the Company’s 1H FY2025 Half Year Results.

### Investor Webinar Registration Details

An investor webinar and Q&A session with Dr Andreas Fouras, Managing Director and Chief Executive Officer of 4DMedical will be held at 11.00am AEDT (10.00am AEST) on Monday, 3 March 2025.

Please register in advance using the following links:

Phone registration: <https://s1.c-conf.com/diamondpass/10045838-a9hg4r.html>

Webcast: <https://ccmediaframe.com/?id=82LWJzyI>

After registering, you will receive a confirmation email containing information about joining the webinar or dial-in details for those who would prefer to join by telephone.

–ENDS–

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate

Chief Financial Officer  
Simon Glover

[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

#### Administration

Company Secretary  
Naomi Lawrie

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

### About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical’s innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the

#### Melbourne

Level 7 Melbourne Connect  
700 Swanston Street  
Carlton VIC 3053  
Tel: +61 (3) 9545 5940

#### Los Angeles

21255 Burbank Boulevard  
Suite 120  
Woodland Hills CA 91367  
Tel: +1 (818) 403-8490

4DMedical Limited  
ABN: 31 161 684 831  
Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)



company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of Imbio, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)